Sales in line with expectations EBIT (loss) 10% better Estimates likley to be revised up 3-5% on EBI...
Redeye comments on Maximum Entertainment ahead of Q1-results (due 21 May) which we expect to be a ba...
We cut our estimates by 2-3% due to lower order intake forecast DK operations should be doing fine F...
Earlier-than-expected cost synergies led to 4% EBITA beat We lift '24e-'26e EBITA by 3-4% on lower o...
Market activity remains muted EBIT estimates cut by 3% for 2025e-26e 2024e EV/EBIT of
Redeye provides its view of Active Biotech's first quarter report of 2024.
Redeye reiterates its valuation following the Q1 2024 report.
Redeye raises its Base Case and forecasts following a strong Q1 report, with the strong gross margin...
Inledningen av 2024 blev som väntat svag. Marknadsläget är tufft och konsumenten är återhållsam men ...
2024 kan bli ett mellanår med strategiska förändringar i fokus.
Lyckegård publicerade den 10 maj år 2024 bolagets delårsrapport för det första kvartalet år 2024.
Redeye concludes that the reported figures mainly were in line with our expectations.
Redeye updates its outlook and fair value range on Lifecare following the company’s Q1 report and an...
Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report.
Avvecklar Mobile… Även om försäljningen av kapacitiva sensorer till mobiltelefontillverkare har börj...
Tar kostnader för åtgärdsplan i kvartalet Omsättningen i kvartalet uppgick till 41,6 mkr, vilket mot...
Blandad kompott i Q1 Nettoomsättningen i Q1(24) ökade med 66% till 12,1 mkr, något under vår förvänt...
G5 reported lower-than-expected topline in Q1, while good cost control supported solid profitability...
Gapwaves' net sales and EBITDA, excluding ACI, surpassed Redeye Research estimates (RRe).
Redeye initiates coverage of Climeon, providing an attractive waste heat recovery solution generatin...
